No UM had a double hit in RPL5, in line with previous studies suggesting RPL5 is a haploinsufficient tumour suppressor, with heterozygous inactivation in glioblastoma (11%), breast cancer (34%) and cutaneous melanoma (28%)39. The gene discussed is RPL5; the disease is breast carcinoma.